Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TMB-365 in HIV-1 Infected Participants
NCT04027387Phase 1Completed
- Sponsor
- TaiMed Biologics
- Start
- Dec 2019
- Primary completion
- Aug 2021
- Modality
- Anti-infectious Disease mAbs
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of TMB-365 in human immunodeficiency virus type 1 infection (HIV-1) (3 cohorts), sponsored by TaiMed Biologics. Primary endpoints: Safety of a single 400mg dose of TMB-365 at 10 weeks, Safety of a single 800mg dose of TMB-365 at 10 weeks and 4 more. Started Dec 2019; status: completed.
02
Drugs
TMB-365
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04027387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04027387.